Nasdaq

Sionna Therapeutics Completes Phase 1 Dosing for NBD1 Stabilizers SION-719 and SION-451, Reports Strong Financial Position and Upcoming Milestones

Sionna Therapeutics completes Phase 1 dosing for NBD1 stabilizers SION-719 and SION-451, with Phase 2a trials set for 2025. Sionna Therapeutics announced the completion of Phase 1 dosing for its NBD1 ...
Seeking Alpha

Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life ...

WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic ...
Seeking Alpha

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that reinforce their potential as either an add-on to standard of care or in a Sionna dual combination ...
manilatimes

Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis

"Today's announcement brings us one step closer to our vision of developing novel NBD1-led proprietary dual combinations to transform the treatment paradigm for CF patients. The successful completion ...